- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07780032
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Restless Legs Syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs that disrupts sleep and quality of life. Current medical therapies often lose effectiveness over time or are associated with significant side effects. Preliminary case reports suggest that spinal cord stimulation (SCS) may improve RLS symptoms.
This single-arm feasibility study will enroll up to 15 adults with severe, treatment-refractory primary RLS. Participants will undergo baseline clinical, neuropsychological, and electrophysiological assessments followed by implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System. Follow-up evaluations will occur through 24 months post-activation. Primary outcomes focus on device and procedure safety. Secondary outcomes evaluate changes in RLS severity, patient-reported outcomes, neurophysiological biomarkers, and device utilization.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Chris Gonzalez
- Telefoonnummer: 2059964318
- E-mail: clgonzalez@uabmc.edu
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- UAB Hospital
-
Contact:
- Chris Gonzalez
- Telefoonnummer: 2059964318
- E-mail: clgonzalez@uabmc.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age >18 years and older.
- Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire.
- IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician.
- RLS symptoms occur ≥ 3 nights per week.
- Willing and able to comply with study procedures.
- Able to provide informed consent.
Exclusion Criteria:
- Age <18 years.
- Neuropathic pain, other than RLS on DN4 questionnaire.
- Any mental or physical limitation that would prevent completing and of the study protocols.
- Active medical implant in the body (i.e., pacemaker).
- History of prior SCS trial or implantation.
- Currently using another device to treat RLS.
- Unable or unwilling to comply with study protocols.
- Other medical conditions that would put the subject at risk as determined by the investigators.
- Pregnant, breastfeeding, or trying to become pregnant.
- Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS.
- Ferritin < 50 ng/mL (excludes iron deficiency).
- HgA1C > 7.5 (excludes unstable diabetes melilitus)
- One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: SCS Implant
|
Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology.
Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and Adverse Events
Tijdsspanne: Baseline through 24 months
|
Frequency, severity, and relationship of device-, stimulation-, and procedure-related adverse events.
|
Baseline through 24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in International Restless Legs Syndrome Scale (IRLS)
Tijdsspanne: Baseline through 24 months
|
The IRLS is a validated 10-item patient-reported measure of Restless Legs Syndrome severity.
Scores range from 0 to 40, with higher scores indicating worse symptom severity.
A decrease in score from baseline indicates improvement.
|
Baseline through 24 months
|
|
Clinician Global Impression Improvement Scale (CGI-I)
Tijdsspanne: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Patient Global Impression of Improvement (PGI-I)
Tijdsspanne: Baseline through 24 months
|
The PGI-I is a patient-reported global rating of change in symptoms and overall condition following treatment.
Scores range from 1 to 7, where 1 = Very much improved and 7 = Very much worse.
Lower scores represent a better outcome and greater perceived improvement.
|
Baseline through 24 months
|
|
Suggested Immobilization Test (SIT)
Tijdsspanne: Baseline through 24 months
|
Baseline through 24 months
|
|
|
PROMIS Sleep, Pain, Anxiety, Depression, Cognition, and Health Measures
Tijdsspanne: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Changes in Neurophysiological Measures of Spinal Cord Stimulation Response
Tijdsspanne: Baseline through 24 months
|
Changes in H-reflexes, somatosensory evoked potentials (SSEPs), EEG measures, and device-recorded ECAPs.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Sleep
Tijdsspanne: Baseline through 24 months
|
Questionnaire assessing perceived sleep quality and difficulty falling asleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater sleep disturbance and a worse outcome.
The T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Pain
Tijdsspanne: Baseline through 24 months
|
Questionnaire assessing the impact of pain on daily activities and sleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater pain interference and a worse outcome.
The T-score range is approximately 30 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Anxiety
Tijdsspanne: Baseline through 24 months
|
Questionnaire assessing fear, anxious mood, and anxiety-related symptoms during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater anxiety and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Depression
Tijdsspanne: Baseline through 24 months
|
Questionnaire assessing depressive symptoms, negative mood, and diminished self-worth during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater depressive symptom burden and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Cognition
Tijdsspanne: Baseline through 24 months
|
Questionnaire assessing perceived cognitive abilities including memory, concentration, and mental acuity.
Responses are converted to PROMIS standardized T-scores .
Higher scores indicate better cognitive functioning and a better outcome.
The T-score range is approximately 20 to 80.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Mental health battery
Tijdsspanne: Baseline through 24 months
|
Assesses overall mental health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Physical Health Battery
Tijdsspanne: Baseline through 24 months
|
Assesses Overall Physical Health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Marshall Holland, MD, University of Alabama at Birmingham
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB-300013464
- 1UG3NS145980-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .